The Use of Anticoagulants in the Prevention of Venous Thrombosis After Myocardial Infarction

Ba, Pussell; Pitney, W. R.

doi:10.5694/j.1326-5377.1972.tb103751.x

Cited by 5 publications

(4 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Kricheff et al (1973) showed in experiments lasting up to 2.5 hours that aspirin reduced thrombus formation on radiological catheters in the vena cava of the cat. Pussell and Pitney (1972), when using low dose heparin for prevention of deep vein thrombosis in humans, showed with radioisotope labelled fibrinogen that the incidence of thrombus formation on 'panic needles' was similar in treated and control patients. With a similar result to that obtained here, Wall ace et al (1973) showed in dogs that systemic heparinization sufficient to prolong the coagulation time significantly minimized thrombus production.…”

Section: Discussionmentioning

confidence: 99%

Effects of Heparin, Aspirin and Dipyridamole on Thrombus Formation on Venous Catheters

Spanos

Hecker

1979

Anaesth Intensive Care

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Effects of Heparin, Aspirin and Dipyridamole on Thrombus Formation on Venous Catheters

Spanos

Hecker

1979

Anaesth Intensive Care

View full text Add to dashboard Cite

show abstract

“…The prophylactic use of full therapeutic doses of heparin in high-risk patients after surgery [51,127,128,199] was not evaluated further because of its inconvenience and the risk of bleeding. However, a number of randomized [86,206,207] and nonrandomized [133,146] studies have reported that therapeutic doses of heparin, alone [86], or followed with oral anticoagulant treatment, prevent venous thrombosis after myocardial infarction.…”

Section: B Prophylaxis With Full Therapeutic Doses Of Heparinmentioning

confidence: 99%

Prevention of Venous Thromboembolism

Gallus¹,

Hirsh²

2008

Semin Thromb Hemost

View full text Add to dashboard Cite

“…Prophylaxis is required for at least L0 days. lntroduction A series of studies between L970 and 197 5 have shown that the incidence of isotopically determined venous thrombosis in patients with acute myocardial infarction varies from 17 Vo to 53Vo, with a mean incidence of 29Vo (1)(2)(3)(4)(5)(6)(7)(8)(9)(10). The incidence of deep venous thrombosis (D.V.T.)…”

mentioning

confidence: 99%

“…The incidence of deep venous thrombosis (D.V.T.) can be reduced with low dose heparin or oral anticoagulants (2,4,8,9), but these treatments are associated with a certain risk bleeding. Because platelets are considered to play a key role in the pathogenesis of thrombosis (11), antiplatelet drugs have been used for the prevention of D. V. T. Antiplatelet drugs are of potential clinical value, because they are easy to administer, they do not require laboratory control in patients after hipand kneesurgery (I2, 13).…”

mentioning

confidence: 99%

The Incidence of Deep Venous Thrombosis in Patients with an Acute Myocardial Infarction Treated with Acenocoumarol or Indobufen

Sh¹,

Jj²,

Ac³

et al. 1982

Thromb Haemost

View full text Add to dashboard Cite

SummaryIn a randomized double blind clinical trial, we compared indobufen, an antiplatelet drug, with acenocoumarol for the prevention of deep venous thrombosis (D. V. T.) in patients with acute myocardial infarction. Therapy was started on admission and continued for 10 days. All patients were screened daily with impedance plethysmography (I.P.G.) and 125I-fibrinogen leg scanning. Diagnosis of D.V.T. was made when either one or both tests became positive. 74 patients were randomized to treatment with indobufen (200 mg b.i.d.) and 76 patients to acenocoumarol (controlled by thrombotest). The incidence of venous thrombosis in patients with indobufen was 11% and in those treated with acenocoumarol 9%. Major bleeding was observed in 2 patients treated with acenocoumarol. In the indobufen group, no bleeding complications or other serious side-effects were observed. The majority of patients developed thrombosis after the first week of admission. For patients with and without thrombosis, there was no significant difference between the two treatment groups concerning the age, the coronary prognostic index, the maximum C.P.K. value, mobility, incidence of congestive heart failure and the site or extent of the infarct. In this study no clinical or laboratory (fibrinogen, platelet count and anti-thrombin III) parameter, either alone or in combination, was of predictive value for the development of D.V.T. It can be concluded that indobufen appears to be as good as acenocoumarol for the prevention of D.V.T. in patients with acute myocardial infarction. Because it is safe and easy to administer, indobufen seems to be preferable. Prophylaxis is required for at least 10 days.

show abstract

The Use of Anticoagulants in the Prevention of Venous Thrombosis After Myocardial Infarction

Cited by 5 publications

References 12 publications

Effects of Heparin, Aspirin and Dipyridamole on Thrombus Formation on Venous Catheters

Effects of Heparin, Aspirin and Dipyridamole on Thrombus Formation on Venous Catheters

Prevention of Venous Thromboembolism

The Incidence of Deep Venous Thrombosis in Patients with an Acute Myocardial Infarction Treated with Acenocoumarol or Indobufen

Contact Info

Product

Resources

About